435 related articles for article (PubMed ID: 31461085)
1. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
2. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
Ahmed SR; Petersen E; Patel R; Migden MR
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
[No Abstract] [Full Text] [Related]
3. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
4. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
5. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
6. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
Patel R; Chang ALS
Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
[TBL] [Abstract][Full Text] [Related]
8. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
10. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
11. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
12. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
13. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K; Tsai KK
Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
[TBL] [Abstract][Full Text] [Related]
15. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
16. Cemiplimab: First Global Approval.
Markham A; Duggan S
Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447
[TBL] [Abstract][Full Text] [Related]
17. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
[TBL] [Abstract][Full Text] [Related]
18. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
